| Compound | GHK-Cu |
|---|---|
| Category | Copper-binding tripeptide |
| Class | Other Injectables |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
GHK-Cu — a copper-binding tripeptide — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A naturally occurring copper-binding tripeptide with a topical cosmetic evidence base for skin appearance — and essentially no human injectable data.
Mechanism of Action
GHK-Cu complexes copper and stimulates wound-repair-associated processes in fibroblasts; cosmetic formulations leverage remodeling signals for skin.
Research and Evidence
Topical studies (largely cosmetic-grade) support modest appearance effects. Injectable human data do not exist, making injection an evidence-free route.
Safety and Side Effects
Topical use has a favorable record; injectable safety is uncharacterized.
Frequently Asked Questions
What is the evidence tier of GHK-Cu?
GHK-Cu is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is GHK-Cu an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for GHK-Cu?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for GHK-Cu studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.